Literature DB >> 26374210

United States Food and Drug Administration Regulation of Gene and Cell Therapies.

Alexander M Bailey1, Judith Arcidiacono2, Kimberly A Benton2, Zenobia Taraporewala2, Steve Winitsky2.   

Abstract

The United States (US) Food and Drug Administration (FDA) is a regulatory agency that has oversight for a wide range of products entering the US market, including gene and cell therapies. The regulatory approach for these products is similar to other medical products within the United States and consists of a multitiered framework of statutes, regulations, and guidance documents. Within this framework, there is considerable flexibility which is necessary due to the biological and technical complexity of these products in general. This chapter provides an overview of the US FDA regulatory oversight of gene and cell therapy products.

Keywords:  Cell therapy; Clinical development; Clinical trial; Gene therapy; Marketing application; Product licensure; Public health; US Food and Drug Administration (US FDA)

Mesh:

Year:  2015        PMID: 26374210     DOI: 10.1007/978-3-319-18618-4_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Prospective Evaluation of a Practical Guideline for Managing Positive Sterility Test Results in Cell Therapy Products.

Authors:  Sandhya R Panch; Thejaswi Bikkani; Vanessa Vargas; Jolynn Procter; James W Atkins; Virginia Guptill; Karen M Frank; Anna F Lau; David F Stroncek
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-09       Impact factor: 5.742

Review 2.  The Landscape of Early Clinical Gene Therapies outside of Oncology.

Authors:  Laure Rittié; Takis Athanasopoulos; Miguel Calero-Garcia; Marie L Davies; David J Dow; Steven J Howe; Alastair Morrison; Ida Ricciardelli; Aurore Saudemont; Laurent Jespers; Timothy M Clay
Journal:  Mol Ther       Date:  2019-09-06       Impact factor: 11.454

Review 3.  Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome.

Authors:  Maria Eugenia Fernández-Santos; Mariano Garcia-Arranz; Enrique J Andreu; Ana Maria García-Hernández; Miriam López-Parra; Eva Villarón; Pilar Sepúlveda; Francisco Fernández-Avilés; Damian García-Olmo; Felipe Prosper; Fermin Sánchez-Guijo; Jose M Moraleda; Agustin G Zapata
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

4.  Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study.

Authors:  Weijia Wu; Yan Huo; Xueying Ding; Yuhong Zhou; Shengying Gu; Yuan Gao
Journal:  Ther Adv Med Oncol       Date:  2020-10-17       Impact factor: 8.168

Review 5.  The golden retriever model of Duchenne muscular dystrophy.

Authors:  Joe N Kornegay
Journal:  Skelet Muscle       Date:  2017-05-19       Impact factor: 4.912

Review 6.  Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.

Authors:  Jonathan H Esensten; Jeffrey A Bluestone; Wendell A Lim
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

Review 7.  Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.

Authors:  Alison Smith; Hugh Manoli; Stacey Jaw; Kimberley Frutoz; Alan L Epstein; Leslie A Khawli; Frank-Peter Theil
Journal:  J Immunol Res       Date:  2016-08-08       Impact factor: 4.818

Review 8.  Regulatory Framework for Academic Investigator-Sponsored Investigational New Drug Development of Cell and Gene Therapies in the USA.

Authors:  Anindya Dasgupta; Kristen Herzegh; H Trent Spencer; Christopher Doering; Eric Day; William P Swaney
Journal:  Curr Stem Cell Rep       Date:  2021-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.